Skip to main content

Advertisement

Fig. 2 | Chinese Journal of Cancer

Fig. 2

From: Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Fig. 2

Overall survival (OS) curves of EGFR-mutated patients treated with TKIs. a OS curves of patients with EGFR 19 del and L858R mutation who received first-line TKI therapy (34.9 vs. 37.5 months, P = 0.566); b OS curves of patients with the EGFR 19 del and L858R mutation who received second-line or greater TKI therapy (26.7 vs. 23.8 months, P = 0.256)

Back to article page